Supernus Pharmaceuticals announced the execution of a royalty financing agreement with HealthCare Royalty Partners.
HC Royalty will make a $30 million cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitram (treprostinil) Extended-Release Tablets by Supernus' partner United Therapeutics Corporation.
Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity